Vladimir Cmiljanovic

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

KIBAG Holding AG engages in the planning, design, and building of living spaces. It also produces building materials and focuses on renaturation and recycling solutions. The company was founded in 1926 and is headquartered in Zurich, Switzerland.

AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom.

Kraftwerk Birsfelden AG engages in the generation, distribution, and supply of CO2-free and clean electricity from renewable and domestic hydroelectric power. The company was founded on September 16, 1950 and is headquartered in Birsfelden, Switzerland.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Grande Dixence SA produces and supplies electrical power. The firm owns the hydroelectric facility at Grande Dixence from which it produces and supplies electricity. The Company was founded in 1950 and is headquartered in Sion, Switzerland.

furrerhugi.ag provides public affairs and corporate communications services. The firm offers its services under the brand names furrerhugi.publicaffairs and furrerhugi.corporate. It also specializes in event consulting, online marketing, and international public relations. The company was founded by Lorenz Furrer and Andreas Hugi on June 1, 2006 and is headquartered in Berne, Switzerland.

Credit Suisse (Schweiz) AG engages in the operation of a bank. Its services include all types of banking, financing, asset management and financial advisory services. The company was founded in 1856 and is headquartered in Zurich, Switzerland.

Innosuisse - Swiss Innovation Agency is a company based in Bern, Switzerland. Innosuisse is the Swiss agency for innovation promotion. The private company promotes science-based innovation for the benefit of the economy and society in Switzerland. The CEO of the company is Annalise Eggimann.

World Minds Management AG is an invitation-only community of 1000 individuals who are making proven contributions in science, the arts, business, and government. The private company is based in Baar, Switzerland. The Swiss company's goal is to improve the quality of decisions as private individuals, role models, and citizens of this planet, and to inspire others to do so. The community is an intellectual oasis that provides an exchange of insights without any ideology or corporate small talk. The community includes Nobel laureates, former directors of the CIA, and professors from prestigious universities. The company does not take applications to join the community, and they will contact individuals if they are interested in joining. The company was founded in 2008 by Rolf Dobelli, and the CEO is Christoph Keese.

Exigen Capital LP operates as a private equity firm. The private company is based in San Francisco, CA.